IL-ADVANCED-CLINICAL
9.3.2022 00:54:08 CET | Business Wire | Press release
Advanced Clinical, a clinical development and strategic resourcing organization committed to providing a better clinical experience across the drug development journey, is pleased to announce that Dr. Andreas Amrein has joined the Executive Team as Senior Vice President of Asia-Pacific (APAC) and Japan as well as Managing Director for Europe and Canada.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220308006375/en/
Dr. Amrein will be instrumental to the organization’s continued expansion and strengthening of Advanced Clinical’s current operations into the APAC region, which include offices in Singapore, Australia and Japan. He’ll also oversee development and expansion opportunities for additional locations across Europe and Canada, complementing the company’s existing footprint inclusive of 10 office locations in Europe as well as an office in Toronto, Canada.
With over 20 years of international leadership experience, Dr. Amrein has led many teams and organizations across over 30 geographies, including Fortune 100 companies (Novartis, Abbott and Shire) and dynamic start-ups.
“From my specialization in rapid commercial expansions, launches, transformations, partnerships and more across Asia and around the globe, I look forward to leveraging my knowledge to help Advanced Clinical further establish quality operations internationally,” said Dr. Amrein.
“We are excited to have Andreas on our team as we continue to expand into the APAC region and Japan,” said Julie Ross, President of Advanced Clinical. “Andreas will be instrumental in accelerating business growth as we diversify our global clinical programs and elevate our clinical strategy for the clients and patients we serve. After our successful entry into the region in 2021 combined with additional APAC office openings planned for 2022, Andreas will undoubtedly help elevate our presence across the APAC, European and Canadian regions as a global leader in clinical research, FSP and strategic resourcing services.”
About Advanced Clinical
Advanced Clinical is a clinical development and strategic resourcing organization committed to providing a better clinical experience across the drug development journey. Our goal is to improve the lives of all those touched by clinical research – approaching each opportunity with foresight, character, resilience and innovation. Based on decades of experience, we help our clients achieve better outcomes by conducting candid conversations and anticipating potential issues through our customized solutions. Visit our website to learn more: www.advancedclinical.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220308006375/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
Galderma Tackles Menopause-related Skin Changes With Global Survey and Clinical Trial Inclusivity30.1.2026 07:00:00 CET | Press release
Results from a global survey of over 4,300 women across five continents presented at IMCAS 2026 reveal a knowledge gap on the impact of menopause on the skin, despite women experiencing around three skin changes during menopause1 Galderma will also host a symposium delving into the challenges and science behind menopause-related skin changes and aesthetic solutions at the congress Galderma is committed to raising awareness of the impact of menopause on the skin, fostering meaningful dialogue between patients and healthcare professionals, and advancing science-backed solutions by incorporating menopausal status into all injectable aesthetics clinical trials Galderma (SIX: GALD) has unveiled findings from a global survey of peri- and post-menopausal women from nine countries exploring the impact of menopause on the skin at the International Master Course on Aging Science (IMCAS) 2026 World Congress in Paris, France, from January 29-31, 2026. The survey found that over 50% of women learne
Andersen Consulting styrker sine cybersikkerhedskompetencer med tilføjelsen af RedLegg30.1.2026 00:18:00 CET | Pressemeddelelse
Andersen Consulting styrker sit cybersikkerhedsudbud gennem en samarbejdsaftale med RedLegg, der er et cybersikkerhedsfirma med speciale i administreret trusselsdetektion og rådgivningsydelser. RedLegg blev grundlagt i 2008 og har hovedsæde i USA. RedLegg tilbyder skræddersyede cybersikkerhedsløsninger med fokus på risikominimering, administrerede sikkerhedstjenester og penetrationstest. Virksomhedens ydelser omfatter blandt andet managed detection and response (MDR), hændelsesrespons, udvikling af sikkerhedspolitikker samt virtuel CISO-rådgivning. RedLegg betjener mellemstore virksomheder inden for finans, forsikring, jura og sundhedssektoren og kombinerer automatisering, trusselsintelligens og et dedikeret Security Operations Center (SOC) for at hjælpe organisationer med at effektivisere deres cybersikkerhedsoperationer og opbygge langsigtet modstandsdygtighed. "Vores fokus har altid været at hjælpe kunder med at skære støjen fra og prioritere det, der virkelig betyder noget – nemlig
Andersen Consulting tilføjer samarbejdsfirmaet HaystackID29.1.2026 21:20:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for cybersikkerhed og teknologi gennem en samarbejdsaftale med HaystackID, en amerikansk udbyder af eDiscovery, juridiske data og cyber discovery-tjenester. HaystackID blev stiftet i 2011 og arbejder tæt sammen med advokatfirmaer, virksomheder og offentlige myndigheder om at håndtere komplekse, dataintensive juridiske sager, herunder civile retssager, myndighedsundersøgelser og interne undersøgelser. Firmaet leverer komplet processtøtte ved hjælp af cyber discovery, digital efterforskning, managed review, compliance og information governance, hvilket hjælper klienter med at identificere, analysere og forsvarligt fremlægge kritiske data. Ved hjælp af proprietære ai-drevne platforme og ekspertledede reviewteams betjener HaystackID klienter i hele Nordamerika og Europa, heriblandt Fortune 100-virksomheder. "I takt med at de juridiske og regulatoriske miljøer bliver mere datadrevne og tidskritiske, fortsætter vi med at udvikle vores kompet
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom